Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

By Z. Younossi, M. Stepanova, Mariam Afendy, Yun Fang, Youssef Younossi, H. Mir, Manirath K. Srishord. Clinical Gastroenterology and Hepatology, 2011

1,091 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, background): “Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide [1-3], affecting up to 25% of the global population [4].”
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Therefore, patients with NAFLD and multiple risk factors such as T2DM and hypertension are at the highest risk for adverse outcomes.((20,101)) Circulating levels of cytokeratin-18 fragments have been investigated extensively as novel biomarkers for the presence of SH in patients with NAFLD.”
Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “The prevalence rates of HBV-related, HCV-related, and alcohol-related liver disease remained generally stable, but the prevalence rate of NAFLD doubled; obesity was an independent predictor of NAFLD.(88) However, it is important to keep in mind that aetiologies of CLD vary worldwide.”